Draximage MAA market report points to growth in lung imaging demand

The Business Research Company says the Draximage MAA market is set for steady expansion through 2035, driven by rising respiratory disease, lung cancer cases and broader use of nuclear imaging. North America led the market in 2025, while Asia-Pacific is expected to grow fastest during the forecast period.

Why it matters: - Draximage MAA is used in nuclear medicine lung imaging, where accurate diagnosis can shape treatment decisions for pulmonary disease and cancer. - Rising respiratory illness, aging populations and expanding imaging capacity are increasing demand for radiopharmaceuticals used in lung scans. - The report points to a market with global growth potential, especially as healthcare systems invest more in diagnostic imaging.

What happened: - The Business Research Company released its Draximage MAA Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on Nov. 3, 2026. - The report says the Draximage MAA market has grown on the back of pulmonary disease prevalence, wider adoption of nuclear imaging, stronger hospital diagnostic capabilities, demand for more accurate lung function assessment and radiotracer innovation. - The report expects continued growth from more respiratory disease, more diagnostic imaging centers, better gamma camera technology, greater focus on early detection and higher healthcare investment. - The report highlights broader use of nuclear medicine imaging, growth in lung function diagnostics, stronger demand for ventilation/perfusion scans, advances in radiopharmaceuticals and improved hospital imaging services as key trends.

The details: - Draximage MAA is a radiopharmaceutical for lung imaging in nuclear medicine. - The product uses macro-aggregated albumin labeled with technetium-99m. - The tracer supports ventilation/perfusion lung scans used to evaluate pulmonary function. - After injection, the radiolabeled particles can be tracked with a gamma camera to assess lung performance and spot abnormalities. - Lung cancer is a major demand driver because the disease requires tools for diagnosis, staging and treatment monitoring. - The American Cancer Society reported about 234,580 new lung cancer cases in the U.S. in January 2024, including 116,310 men and 118,270 women. - The American Cancer Society also reported 125,070 lung cancer deaths in the U.S. in January 2024. - Medical imaging demand is rising because of an aging population, chronic disease prevalence, better healthcare infrastructure and preference for minimally invasive procedures. - The UK National Health Service reported MRI referrals from general practitioners rose from 8,695 in January 2022 to 8,745 in January 2023. - The UK National Health Service recorded 43.4 million imaging tests in England between February 2022 and January 2023. - The geriatric population is another growth factor because older adults often need precise lung function diagnostics. - The Population Reference Bureau projects the number of Americans age 65 and older will rise from 58 million in 2022 to 82 million by 2050. - The Population Reference Bureau projects that age group’s share of the U.S. population will increase from 17% to 23% by 2050. - North America held the largest market share in 2025. - Asia-Pacific is expected to grow the fastest during the forecast period. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 report edition includes market attractiveness scoring, TAM analysis, a company scoring matrix, Excel dashboards, market hotspot infographics, and key technology and future trend analysis. - The release includes a free sample report at More information. - The full report is available at the full report.

Between the lines: - The report frames Draximage MAA as part of a broader shift toward more precise nuclear imaging for lung disease. - The fastest growth forecast for Asia-Pacific suggests demand may be spreading beyond established markets as diagnostic infrastructure improves. - The added strategic tools in the 2026 report signal that buyers and investors are looking beyond market size alone and toward competitive positioning and opportunity mapping.

What's next: - The market is expected to keep expanding through 2035 as respiratory disease burden and diagnostic imaging use rise. - Further uptake of nuclear medicine imaging and better imaging equipment could support broader clinical use of Draximage MAA. - More imaging centers and healthcare investment may widen access in faster-growing regions, especially Asia-Pacific.

The bottom line: - Draximage MAA is positioned as a niche but growing imaging product tied to major demand drivers: lung disease, cancer diagnostics, aging populations and broader use of nuclear medicine.